-

Revvity to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.

Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.

To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations website following the event.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Contacts

Investor Relations
Steve Willoughby
steve.willoughby@revvity.com

Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Revvity

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Investor Relations
Steve Willoughby
steve.willoughby@revvity.com

Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com

More News From Revvity

Revvity to Hold Earnings Call on November 3, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o...

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird’s 2026 Global Healthcare Conference Tuesday, September...
Back to Newsroom